(Article 223-16 of General Regulation of the French financial markets authority)

Mechelen, België; 16 mei 2024; 22:01 CET ; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.614.000 inschrijvingsrechten heeft gecreëerd onder nieuwe inschrijvingsrechtenplannen ten gunste van bepaalde leden van het personeel van de vennootschap en haar dochtervennootschappen.

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries.

Daix (France), Long Island City (New York, United States), le 16 mai 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH ») et d’autres maladies avec un besoin médical non satisfait significatif, a annoncé aujourd'hui la recommandation positive de la quatrième réunion du Data Monitoring Committee (DMC) de poursuivre l'étude clinique de Phase III, NATiV3, évaluant lanifibranor chez des patients atteints de la MASH/NASH sans modification du protocole actuel.

Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the positive recommendation from the fourth scheduled meeting of the Data Monitoring Committee (“DMC”) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with MASH/NASH without modification to the current trial protocol.

Oslo, 16 May 2024 - An Extraordinary General Meeting in Adevinta ASA (ADE) was held on 16 May 2024 as a digital meeting. All agenda items were adopted.

IDEX Biometrics ASA held its annual general meeting on 16 May 2024. 95.3 million shares or 34% of the capital was represented at the meeting.

PRESS RELEASE

Oslo, Norway – 16 May 2024 - IDEX Biometrics will give a webcast presentation today at 09:00 CET in connection with its interim report for the first quarter of 2024. The presentation will be held by Vince Graziani, Chief Executive Officer, and Catharina Ekløf, Chief Commercial and Operating Officer. The webcast presentation can be viewed at the following link:

Paris, le 16 mai 2024

Oslo, Norway – 16 May 2024 - IDEX Biometrics ASA’s interim report for the first quarter of 2024 is attached to this notice (link below) The interim report is also available on the IDEX Biometrics website: www.idexbiometrics.com/investors/interim-results/

Communiqué de presse

ENDEAVOUR ANNOUNCES TRANSACTION IN OWN SHARES

Utstedernavn: IDEX Biometrics ASA

Issuer name: IDEX Biometrics ASA

Press release

The board of directors of Vastned Belgium NV (Euronext: VASTB, “Vastned Belgium” or the “Company”) has requested the committee of independent directors of the Company (the “Committee”) to issue an opinion in application of article 7:97 of the Belgian Companies and Associations Code (the “BCAC”) on the conclusion of an agreement entitled “Merger Protocol” (the “Merger Protocol”) between the Company and Vastned Retail NV, a listed public limited liability company incorporated under Dutch law, having its corporate seat in Amsterdam, the Netherlands, and its principal place of business at Mercuriusplein 11, 2132 HA Hoofddorp, the Netherlands and registered in the trade register of the Dutch Chamber of Commerce (Kamer van Koophandel) under number 24262564 (“Vastned Retail” and together with the Company, the “Parties” and, together with their affiliated companies, the “Group”).

De raad van bestuur van Vastned Belgium NV (Euronext: VASTB, ‘Vastned Belgium’ of de ‘Vennootschap’) heeft het comité van onafhankelijke bestuurders van de Vennootschap (het ‘Comité’) verzocht om een advies uit te brengen in toepassing van artikel 7:97 van het wetboek van vennootschappen en verenigingen (het ‘WVV’) over het sluiten van een overeenkomst getiteld ‘Merger Protocol’ (het ‘Fusieprotocol’) tussen de Vennootschap en Vastned Retail N.V., een genoteerde naamloze vennootschap naar Nederlands recht, met statutaire zetel te Amsterdam, Nederland, en met hoofdkantoor te Mercuriusplein 11, 2132 HA Hoofddorp, Nederland en ingeschreven in het handelsregister van de Nederlandse Kamer van Koophandel onder nummer 24262564 (‘Vastned Retail’ en gezamenlijk met de Vennootschap, de ‘Partijen’ en, tezamen met hun verbonden vennootschappen, de ‘Groep’).

The board of directors of Vastned Belgium NV (Euronext: VASTB, “Vastned Belgium” or the “Company”) has requested the committee of independent directors of the Company (the “Committee”) to issue an opinion in application of article 7:97 of the Belgian Companies and Associations Code (the “BCAC”) on the conclusion of an agreement entitled “Merger Protocol” (the “Merger Protocol”) between the Company and Vastned Retail NV, a listed public limited liability company incorporated under Dutch law, having its corporate seat in Amsterdam, the Netherlands, and its principal place of business at Mercuriusplein 11, 2132 HA Hoofddorp, the Netherlands and registered in the trade register of the Dutch Chamber of Commerce (Kamer van Koophandel) under number 24262564 (“Vastned Retail” and together with the Company, the “Parties” and, together with their affiliated companies, the “Group”).

• Vastned Retail and Vastned Belgium intend to merge Vastned Retail into Vastned Belgium, to be named “Vastned”• The Merger aims to generate value for Vastned and its stakeholders, including:   o Simplification of organizational and governance structure, while continuing current successful strategy;   o Expected future recurring annual operational cost synergies of approx. EUR 2.0 - 2.5 million;   o Optimized debt financing;   o Increased free float and liquidity;   o One single listed platform under Belgium’s REIT regime;   o More portfolio diversification;   o Future ability to pursue accretive growth• One listed organization with trading on Euronext Brussels and Euronext Amsterdam, with an expected increase in free float and liquidity for shareholders and a more interesting profile for equity analyst coverage• Vastned will be headquartered in Belgium with a board of directors comprised of five individuals, chaired by Lieven Cuvelier• Sven Bosman will become CEO of Vastned• The Merger is expected to become effective on 1 January 2025, following shareholder approval and satisfaction of other customary conditions• At completion, Vastned Retail shareholders will receive 0.839 Vastned Belgium share for each outstanding Vastned Retail share• To mitigate the immediate impact on the cash dividend for shareholders of Vastned Belgium in light of the different yield profile of Vastned Retail compared to Vastned Belgium, Vastned Belgium will declare an additional dividend of 1.00 per share, to be paid to its pre-merger shareholders in January 2025• Vastned Retail will declare and pay an interim dividend of EUR 1.70 per share in December 2024 (with no interim dividend to be declared and paid by Vastned Retail in August 2024)• Vastned Belgium will declare and pay an interim dividend of EUR 2.30 per share in December 2024• The Vastned Retail Boards as well as the independent directors of Vastned Belgium unanimously support and recommend the Merger• Vastned Retail shareholders, being entities controlled by Messrs. Van Herk, Meulman, De Jonge and Niessen and ICAMAP Real Estate Securities Fund, representing, in the aggregate, more than 42% of the voting rights in Vastned Retail support the simplification and strategic restructuring of the group into one listed organization and have committed to vote in favor of the Merger

• Vastned Retail and Vastned Belgium intend to merge Vastned Retail into Vastned Belgium, to be named “Vastned”• The Merger aims to generate value for Vastned and its stakeholders, including:   o Simplification of organizational and governance structure, while continuing current successful strategy;   o Expected future recurring annual operational cost synergies of approx. EUR 2.0 - 2.5 million;   o Optimized debt financing;   o Increased free float and liquidity;   o One single listed platform under Belgium’s REIT regime;   o More portfolio diversification;   o Future ability to pursue accretive growth• One listed organization with trading on Euronext Brussels and Euronext Amsterdam, with an expected increase in free float and liquidity for shareholders and a more interesting profile for equity analyst coverage• Vastned will be headquartered in Belgium with a board of directors comprised of five individuals, chaired by Lieven Cuvelier• Sven Bosman will become CEO of Vastned• The Merger is expected to become effective on 1 January 2025, following shareholder approval and satisfaction of other customary conditions• At completion, Vastned Retail shareholders will receive 0.839 Vastned Belgium share for each outstanding Vastned Retail share• To mitigate the immediate impact on the cash dividend for shareholders of Vastned Belgium in light of the different yield profile of Vastned Retail compared to Vastned Belgium, Vastned Belgium will declare an additional dividend of 1.00 per share, to be paid to its pre-merger shareholders in January 2025• Vastned Retail will declare and pay an interim dividend of EUR 1.70 per share in December 2024 (with no interim dividend to be declared and paid by Vastned Retail in August 2024)• Vastned Belgium will declare and pay an interim dividend of EUR 2.30 per share in December 2024• The Vastned Retail Boards as well as the independent directors of Vastned Belgium unanimously support and recommend the Merger• Vastned Retail shareholders, being entities controlled by Messrs. Van Herk, Meulman, De Jonge and Niessen and ICAMAP Real Estate Securities Fund, representing, in the aggregate, more than 42% of the voting rights in Vastned Retail support the simplification and strategic restructuring of the group into one listed organization and have committed to vote in favor of the Merger

VEON 1Q24 Trading Update: Accelerating USD Growth, Strong Operational Execution

• Vastned Retail en Vastned Belgium zijn voornemens om Vastned Retail te fuseren in Vastned Belgium, dat de naam "Vastned" zal krijgen.

COMMUNIQUE DE PRESSE

PRESS RELEASE

Umicore announces CEO succession

Umicore annonce la succession de son CEO

Umicore kondigt CEO-opvolging aan

Communiqué de presse

Paris, 2 June 2021

Transaction in Own Shares

Paris, May 15, 2024

PRESS RELEASEParis, 15 May, 2024

COMMUNIQUE DE PRESSE

COMMUNIQUE

PRESS INFORMATIONHeading: 1st quarter 2024 revenues        Nanterre, May 15, 2024 (after trading)

INFORMATION PRESSERubrique : C.A. 1er trimestre 2024        Nanterre, le 15 mai 2024 (après Bourse)

Baku and Barcelona, 15 May 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, is delighted to announce that it has signed a Memorandum of Understanding (MoU) with Beeline Kazakhstan, the GSMA and the Barcelona Supercomputing Center - Centro Nacional de Supercomputacion (BSC-CNS) to explore collaboration on the development of artificial intelligence and language technologies for languages with low digital resources.

The Annual General Meeting of Alvotech S.A. will be held on Friday June 7, 2024, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg.

Aðalfundur Alvotech S.A. verður haldinn föstudaginn 7. júní 2024, kl. 09.00 CEST á skrifstofu Arendt & Medernach S.A að 41A Avenue John F. Kennedy, L-1855 Lúxemborg.

Euronext N.V. Annual General Meeting results

Oslo, 14 May 2024

At the close of business on 14 May 2024, Larry Ciaccia, chair of the board of IDEX Biometrics, and Morten Opstad, board member, held the following voting rights in IDEX, for the purpose of the annual general meeting on 16 May 2024:

Aksjene i Equinor ASA (OSE: EQNR; NYSE: EQNR) vil fra og med i dag handles eksklusiv kontantutbytte for fjerde kvartal 2023 slik det fremgår under.